BOJ keeps interest rates flat, but flags rate hikes on rising inflation, GDP
Andrew Guggenhime, the President and Chief Financial Officer of Vaxcyte, Inc. (NASDAQ:PCVX), recently sold shares worth $670,822, according to a filing with the Securities and Exchange Commission. The transactions occurred on February 18, 2025, as part of a planned 10b5-1 trading arrangement. According to InvestingPro data, Vaxcyte currently trades near its Fair Value with a market capitalization of $10.4 billion, while analysts maintain a strong buy consensus with price targets ranging from $135 to $163.
The sales involved two separate transactions. The first sale included 6,182 shares at a weighted-average price within the range of $83.17 to $84.10. The second transaction consisted of 1,818 shares, sold at prices ranging from $84.125 to $84.985. Want deeper insights into insider trading patterns and company financials? InvestingPro subscribers get access to comprehensive insider transaction analysis and 6 additional ProTips about Vaxcyte’s financial health.
Additionally, Guggenhime exercised stock options to acquire 8,000 shares of common stock at a price of $5.35 per share, totaling $42,800. Following these transactions, Guggenhime holds 109,491 shares in Vaxcyte, which is based in San Carlos, California. The company maintains a strong financial position with a current ratio of 17.9x and holds more cash than debt on its balance sheet, earning a "Fair" overall financial health score from InvestingPro.
In other recent news, Vaxcyte, Inc. has commenced the final stage of its Phase 2 study for the VAX-31 pneumococcal conjugate vaccine candidate. This study will evaluate the vaccine’s safety, tolerability, and immunogenicity in healthy infants, with topline data expected in mid-2026. Goldman Sachs has initiated coverage of Vaxcyte with a Buy rating, citing strong clinical data for VAX-31 and the company’s proprietary technology platform as key factors. The firm is optimistic about upcoming data for VAX-24 in the infant population, anticipated in the first quarter of 2025, viewing it as a potential catalyst for the company’s stock. Additionally, Vaxcyte has expanded its headquarters in San Carlos, California, through an amended lease agreement that consolidates previous arrangements into a single lease for 258,581 rentable square feet. This expansion includes phased leasing of additional floors, with a lease term of 120 months once all phases commence. Vaxcyte has also subleased a portion of its space to Iovance Biotherapeutics (NASDAQ:IOVA), Inc., with the sublease set to begin by December 15, 2024. These developments underscore Vaxcyte’s growth and ongoing efforts in advancing its vaccine pipeline and corporate infrastructure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.